비교리스트

 카트 문의
시장보고서
상품코드
1321048

사이코바이오틱스 시장 : 세계 산업 규모, 점유율, 동향, 경쟁, 기회 및 예측(2018-2028년)

Psychobiotics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent, By Form, By Application, By Region and Competition
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 110 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 사이코바이오틱스 시장은 2024-2028년의 예측 기간 동안 놀라운 성장세를 보일 것으로 예상됩니다.

시장 성장은 특히 스트레스, 불안, 수면장애와 같은 정신 건강 문제에 대한 관심 증가에 기인한 것으로 보이며, Global Burden of Diseases, Injuries, and Risk Factors Study(GBD) 2019에 따르면, 불안 장애와 우울증이 장애는 가장 무력한 두 가지 정신질환으로 2019년 세계 질병 부담의 주요 원인 중 상위 25위 안에 들었습니다. 이 부담은 남녀를 불문하고 세계적으로 고르게 나타나고 있습니다. 더 중요한 것은 두 장애 모두 그 영향을 줄이는 치료법의 강력한 증거에도 불구하고 세계 유병률과 부담이 감소하지 않았다는 것입니다. 또한, 코로나19의 갑작스러운 발생과 2020년부터 2021년까지 세계적으로 바이러스를 억제하기 위해 시행된 봉쇄 조치로 인해 사람들의 정신 건강 문제가 증가하고 있습니다.

불안과 우울증을 치료하는 프로바이오틱스에 대한 수요 증가

미생물-장-뇌축에 영향을 미침으로써 프로바이오틱스는 기분과 숙주의 건강에 영향을 미칠 수 있습니다. 스트레스, 불안, 우울증은 모두 감정이 점차 희석되는 것과 관련이 있습니다. 불안은 스트레스에 대한 반응이지만, 지속되고 잘못 치료하면 우울증과 같은 더 심각한 정신 질환으로 발전할 수 있습니다. 스트레스는 일반적으로 육체적 또는 정신적으로 부담스러운 다양한 사건이나 긴급한 상황에 대한 단기간의 반응으로 인해 발생합니다. 많은 연구에서 사람들의 불안과 우울증 사이에 미묘한 관계가 있음을 발견했습니다. 호주의 데이터에 따르면 임상적으로 심각한 불안을 가진 환자의 28%는 우울증을 동반하고 있으며, 우울증 환자의 약 57%는 불안을 동반하고 있습니다.

여러 연구에 따르면 장내 세균총이 기분 조절에 긍정적인 역할을 한다는 것이 입증되어 프로바이오틱스가 광범위하게 활용되고 있습니다. 여러 연구에 따르면, 주요우울증 환자에서 프로테오박테리아, 박테로이데테스, 액티노박테리아의 양이 증가하고, 파미큐테스의 양은 현저하게 감소하는 것으로 나타났습니다. 프로바이오틱스는 중추신경계의 활동과 행동에 다양한 영향을 미칩니다. 첫째, 일부 국소 박테리아는 숙주 세포의 세로토닌, 도파민, GABA와 같은 신경 전달 물질의 생성을 유도할 수 있습니다. 또한 미생물은 뇌의 신경전달물질 수용체 발현을 변화시킬 수 있습니다. 프로바이오틱스는 항염증성 사이토카인을 증가시키고 염증성 사이토카인을 감소시킴으로써 전신의 염증을 억제하는 데도 도움이 됩니다.

프로바이오틱스가 정신 질환에 효과적이라는 사실에 따라 스트레스, 불안, 우울증 등 정신 질환 치료에 프로바이오틱스의 적용을 연구하는 임상시험이 급증하고 있습니다. 따라서 이는 향후 몇 년동안 세계 사이코바이오틱스 시장 확대에 더욱 기여하고 있습니다.

불안과 우울증의 급증

사람들에게 가장 빈번하게 영향을 미치는 두 가지 정신 질환은 우울증과 불안 장애입니다. 기분 장애의 주요 유형 중 하나인 우울증은 기분 저하와 흥미 상실을 특징으로 하며, 죄책감, 절망감, 식욕 부진, 불면증 등을 동반하는 경우가 많습니다. 불안은 긴장감, 걱정, 두려움, 두근거림, 떨림, 소화기, 호흡기, 순환기 계통의 문제 등 뚜렷한 객관적 이유가 없는 신체적 변화를 동반합니다. 세계보건기구(WHO)의 추산에 따르면 2015년에는 불안장애가 세계 인구의 3.6%, 우울증이 4.4%에 영향을 미쳤습니다.

코로나19 팬데믹은 세계 환자들의 정신건강에도 악영향을 끼쳤는데, 란셋(Lancet)지에 발표된 연구에 따르면 불안장애 발병률은 세계적으로 남녀 모두 25.6% 증가했다고 합니다. 우울증 유병률은 27.6% 증가했습니다. 두 질환의 유병률 증가는 남성보다 여성에서 더 두드러지게 나타났습니다. 우울증 유병률은 여성에서 29.8% 증가한 반면, 불안장애 유병률은 여성에서 27.9%, 남성에서 21.7% 증가했습니다.

소비자 인식 증가

시장 성장은 소비자의 소화를 포함한 신체 전반의 과정을 개선하는 사이코바이오틱스의 능력에 의해 촉진될 것으로 예상됩니다. 또한, 위장 및 면역 체계와 같은 특정 소비자 수요를 충족시킬 수 있는 사이코바이오틱스의 능력과 최근 제품 개발의 발전으로 인해 수요도 증가할 것으로 예상됩니다.

Kelly Group이 2019년 건강 지향적인 미국인 2,100명을 대상으로 실시한 세계 여론조사에 따르면, 응답자의 62%는 프로바이오틱스가 무엇인지 알고 있으며, 32%는 지난 6개월 동안 프로바이오틱스를 사용해 본 적이 있다고 답했습니다. 프로바이오틱스를 알고 있는 미국인의 79%는 소화기 건강 개선이 제품에서 기대하는 가장 중요한 건강 효과라고 답했습니다.

또한, 제조업체들은 새로운 형태, 식습관, 패키지의 혁신적인 사이코바이오틱스 관련 제품을 개발하는 데 주력하고 있습니다. 제조업체들이 비건 및 글루텐 프리 사이코바이오틱스 제품을 선보이면서 건강을 중시하는 비건 소비자들 사이에서 사이코바이오틱스에 대한 수요가 증가하고 있습니다. 이에 따라 더 많은 사람들이 더 나은 건강한 라이프스타일을 위해 프로바이오틱스를 생활에 도입하고 있습니다. 이는 향후 몇 년동안 사이코바이오틱스 산업을 강화할 가능성이 높습니다.

사용 가능한 커스터마이징

TechSci 리서치는 주어진 시장 데이터를 사용하여 기업의 특정 요구에 따라 맞춤형을 제공합니다. 보고서에서 다음과 같은 커스터마이징이 가능합니다.

기업 소개

  • 추가 시장 진출기업(최대 5개사)에 대한 심층 분석 및 프로파일링

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

  • 시장 개요
  • 주요 시장 세분화 개요
  • 주요 시장 기업 개요
  • 주요 지역/국가 개요
  • 시장 성장 촉진요인, 과제, 동향 개요

제4장 고객의 소리

  • 브랜드 인지도
  • 선호 구입 방법
  • 정신 질환 주요 요인
  • 사이코바이오틱스제품에 대한 소비 의욕
  • 섭취 후에 관찰되는 일반적인 심리학적 효과

제5장 임상시험 분석

제6장 특허 분석

제7장 세계의 사이코바이오틱스 시장 전망

  • 시장 규모와 예측
    • 매출 및 판매 수량별
  • 시장 점유율과 예측
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 지역별
    • 기업별
  • 제품 시장 맵
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 지역별
  • 가격 분석

제8장 북미의 사이코바이오틱스시장 전망

  • 시장 규모와 예측
    • 매출 및 판매 수량별
  • 시장 점유율과 예측
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 국가별
  • 가격 분석
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제9장 유럽의 사이코바이오틱스시장 전망

  • 시장 규모와 예측
    • 매출 및 판매 수량별
  • 시장 점유율과 예측
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 국가별
  • 가격 분석
  • 유럽 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인
    • 스웨덴
    • 폴란드
    • 슬로바키아

제10장 아시아태평양의 사이코바이오틱스시장 전망

  • 시장 규모와 예측
    • 매출 및 판매 수량별
  • 시장 점유율과 예측
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 국가별
  • 가격 분석
  • 아시아태평양 국가별 분석
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주
    • 대만
    • 말레이시아
    • 싱가포르

제11장 남미의 사이코바이오틱스시장 전망

  • 시장 규모와 예측
    • 매출 및 판매 수량별
  • 시장 점유율과 예측
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 국가별
  • 가격 분석
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제12장 중동 및 아프리카의 사이코바이오틱스시장 전망

  • 시장 규모와 예측
    • 매출 및 판매 수량별
  • 시장 점유율과 예측
    • 사이코바이오틱스별
    • 형태별
    • 용도별
    • 국가별
  • 가격 분석
  • 중동 및 아프리카(MEA) : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제13장 시장 역학

  • 성장 촉진요인
  • 과제

제14장 시장 동향과 발전

  • 임상시험수 증가
  • 경쟁 심화와 향후 기술 혁신
  • 인수합병(M&A)

제15장 경쟁 구도

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials(As Reported)
  • Recent Developments
  • SWOT Analysis
    • InnovixLabs
    • Bened Biomedical Co., Ltd
    • Nutrimmun GmbH
    • Kerry Group Plc.
    • Sabinsa Corporation
    • Lallemand Health Solutions Inc.
    • DuPont de Nemours, Inc.
    • Uplift Food Pty Ltd.
    • Nature's Bounty Co. Ltd.
    • BioGaia Group
    • The Life Extension Foundation
    • Lifted Naturals

제16장 전략적 제안

LSH 23.08.23

Global Psychobiotics market is projected to accomplish extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, and sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and the imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.

A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.

Increasing Demand for Probiotics to Treat Anxiety and Depression

By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.

Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines-a pattern connected to the control of intestinal permeability-probiotics also assist in reducing systemic inflammation.

Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.

Surge in Cases of Anxiety and Depression

The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.

The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.

Rising Consumer Awareness

The market's growth is also anticipated to be fueled by the psychobiotic capacity to improve the body's general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.

According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.

In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.

Market Segmentation

Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.

Company Profiles

Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

Report Scope

In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent:

  • Streptococcus
  • Bifidobacterium
  • Lactobacillus
  • Clostridium
  • Others

Psychobiotics Market, By Form:

  • Powder
  • Liquid/Fluid
  • Tablets
  • Others

Psychobiotics Market, By Application:

  • Stress Management
  • Mood Health & Mood Upliftment
  • Depression
  • Anxiety
  • Sleep Problems
  • Others

Psychobiotics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
    • Sweden
    • Poland
    • Slovakia
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Taiwan
    • Malaysia
    • Singapore
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Brand Awareness
  • 4.2. Preferred Mode of Purchase
  • 4.3. Major Factors Contributing to Mental Illness
  • 4.4. Willingness towards Psychobiotics Consumption
  • 4.5. Commonly Observed Psychological Effect Post Consumption

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patents Analysis

7. Global Psychobiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Product Market Map
    • 7.3.1. By Psychotropic Agent
    • 7.3.2. By Form
    • 7.3.3. By Application
    • 7.3.4. By Region
  • 7.4. Pricing Analysis

8. North America Psychobiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 8.2.4. By Country
  • 8.3. Pricing Analysis
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Psychobiotics Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value & Volume
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Psychotropic Agent
        • 8.4.1.2.2. By Form
        • 8.4.1.2.3. By Application
      • 8.4.1.3. Pricing Analysis
    • 8.4.2. Mexico Psychobiotics Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value & Volume
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Psychotropic Agent
        • 8.4.2.2.2. By Form
        • 8.4.2.2.3. By Application
      • 8.4.2.3. Pricing Analysis
    • 8.4.3. Canada Psychobiotics Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value & Volume
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Psychotropic Agent
        • 8.4.3.2.2. By Form
        • 8.4.3.2.3. By Application
      • 8.4.3.3. Pricing Analysis

9. Europe Psychobiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 9.2.4. By Country
  • 9.3. Pricing Analysis
  • 9.4. Europe: Country Analysis
    • 9.4.1. France Psychobiotics Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value & Volume
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Psychotropic Agent
        • 9.4.1.2.2. By Form
        • 9.4.1.2.3. By Application
      • 9.4.1.3. Pricing Analysis
    • 9.4.2. Germany Psychobiotics Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value & Volume
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Psychotropic Agent
        • 9.4.2.2.2. By Form
        • 9.4.2.2.3. By Application
      • 9.4.2.3. Pricing Analysis
    • 9.4.3. United Kingdom Psychobiotics Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value & Volume
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Psychotropic Agent
        • 9.4.3.2.2. By Form
        • 9.4.3.2.3. By Application
      • 9.4.3.3. Pricing Analysis
    • 9.4.4. Italy Psychobiotics Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value & Volume
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Psychotropic Agent
        • 9.4.4.2.2. By Form
        • 9.4.4.2.3. By Application
      • 9.4.4.3. Pricing Analysis
    • 9.4.5. Spain Psychobiotics Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value & Volume
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Psychotropic Agent
        • 9.4.5.2.2. By Form
        • 9.4.5.2.3. By Application
      • 9.4.5.3. Pricing Analysis
    • 9.4.6. Sweden Psychobiotics Market Outlook
      • 9.4.6.1. Market Size & Forecast
        • 9.4.6.1.1. By Value & Volume
      • 9.4.6.2. Market Share & Forecast
        • 9.4.6.2.1. By Psychotropic Agent
        • 9.4.6.2.2. By Form
        • 9.4.6.2.3. By Application
      • 9.4.6.3. Pricing Analysis
    • 9.4.7. Poland Psychobiotics Market Outlook
      • 9.4.7.1. Market Size & Forecast
        • 9.4.7.1.1. By Value & Volume
      • 9.4.7.2. Market Share & Forecast
        • 9.4.7.2.1. By Psychotropic Agent
        • 9.4.7.2.2. By Form
        • 9.4.7.2.3. By Application
      • 9.4.7.3. Pricing Analysis
    • 9.4.8. Slovakia Psychobiotics Market Outlook
      • 9.4.8.1. Market Size & Forecast
        • 9.4.8.1.1. By Value & Volume
      • 9.4.8.2. Market Share & Forecast
        • 9.4.8.2.1. By Psychotropic Agent
        • 9.4.8.2.2. By Form
        • 9.4.8.2.3. By Application
      • 9.4.8.3. Pricing Analysis

10. Asia-Pacific Psychobiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 10.2.4. By Country
  • 10.3. Pricing Analysis
  • 10.4. Asia-Pacific: Country Analysis
    • 10.4.1. China Psychobiotics Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Psychotropic Agent
        • 10.4.1.2.2. By Form
        • 10.4.1.2.3. By Application
      • 10.4.1.3. Pricing Analysis
    • 10.4.2. India Psychobiotics Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Psychotropic Agent
        • 10.4.2.2.2. By Form
        • 10.4.2.2.3. By Application
      • 10.4.2.3. Pricing Analysis
    • 10.4.3. South Korea Psychobiotics Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Psychotropic Agent
        • 10.4.3.2.2. By Form
        • 10.4.3.2.3. By Application
      • 10.4.3.3. Pricing Analysis
    • 10.4.4. Japan Psychobiotics Market Outlook
      • 10.4.4.1. Market Size & Forecast
        • 10.4.4.1.1. By Value & Volume
      • 10.4.4.2. Market Share & Forecast
        • 10.4.4.2.1. By Psychotropic Agent
        • 10.4.4.2.2. By Form
        • 10.4.4.2.3. By Application
      • 10.4.4.3. Pricing Analysis
    • 10.4.5. Australia Psychobiotics Market Outlook
      • 10.4.5.1. Market Size & Forecast
        • 10.4.5.1.1. By Value & Volume
      • 10.4.5.2. Market Share & Forecast
        • 10.4.5.2.1. By Psychotropic Agent
        • 10.4.5.2.2. By Form
        • 10.4.5.2.3. By Application
      • 10.4.5.3. Pricing Analysis
    • 10.4.6. Taiwan Psychobiotics Market Outlook
      • 10.4.6.1. Market Size & Forecast
        • 10.4.6.1.1. By Value & Volume
      • 10.4.6.2. Market Share & Forecast
        • 10.4.6.2.1. By Psychotropic Agent
        • 10.4.6.2.2. By Form
        • 10.4.6.2.3. By Application
      • 10.4.6.3. Pricing Analysis
    • 10.4.7. Malaysia Psychobiotics Market Outlook
      • 10.4.7.1. Market Size & Forecast
        • 10.4.7.1.1. By Value & Volume
      • 10.4.7.2. Market Share & Forecast
        • 10.4.7.2.1. By Psychotropic Agent
        • 10.4.7.2.2. By Form
        • 10.4.7.2.3. By Application
      • 10.4.7.3. Pricing Analysis
    • 10.4.8. Singapore Psychobiotics Market Outlook
      • 10.4.8.1. Market Size & Forecast
        • 10.4.8.1.1. By Value & Volume
      • 10.4.8.2. Market Share & Forecast
        • 10.4.8.2.1. By Psychotropic Agent
        • 10.4.8.2.2. By Form
        • 10.4.8.2.3. By Application
      • 10.4.8.3. Pricing Analysis

11. South America Psychobiotics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 11.2.4. By Country
  • 11.3. Pricing Analysis
  • 11.4. South America: Country Analysis
    • 11.4.1. Brazil Psychobiotics Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Psychotropic Agent
        • 11.4.1.2.2. By Form
        • 11.4.1.2.3. By Application
      • 11.4.1.3. Pricing Analysis
    • 11.4.2. Argentina Psychobiotics Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Psychotropic Agent
        • 11.4.2.2.2. By Form
        • 11.4.2.2.3. By Application
      • 11.4.2.3. Pricing Analysis
    • 11.4.3. Colombia Psychobiotics Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Psychotropic Agent
        • 11.4.3.2.2. By Form
        • 11.4.3.2.3. By Application
      • 11.4.3.3. Pricing Analysis

12. Middle East and Africa Psychobiotics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 12.2.4. By Country
  • 12.3. Pricing Analysis
  • 12.4. MEA: Country Analysis
    • 12.4.1. South Africa Psychobiotics Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Psychotropic Agent
        • 12.4.1.2.2. By Form
        • 12.4.1.2.3. By Application
      • 12.4.1.3. Pricing Analysis
    • 12.4.2. Saudi Arabia Psychobiotics Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Psychotropic Agent
        • 12.4.2.2.2. By Form
        • 12.4.2.2.3. By Application
      • 12.4.2.3. Pricing Analysis
    • 12.4.3. UAE Psychobiotics Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Psychotropic Agent
        • 12.4.3.2.2. By Form
        • 12.4.3.2.3. By Application
      • 12.4.3.3. Pricing Analysis

13. Market Dynamics

  • 13.1. Drivers
    • 13.1.1. Increased Use of Probiotics for Anxiety and Depression
    • 13.1.2. Surge in Subjects with Anxiety and Depression
    • 13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
  • 13.2. Challenges
    • 13.2.1. Detrimental Effects on Physical Health
    • 13.2.2. Endocrine and Metabolic Side Effects
    • 13.2.3. Unavailability in Developing Countries and Under-Developed Countries

14. Market Trends & Developments

  • 14.1. Increasing Number of Clinical Trials
  • 14.2. Increased Competition and Upcoming Innovations
  • 14.3. Mergers & Acquisitions

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As Reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. InnovixLabs
    • 15.6.2. Bened Biomedical Co., Ltd
    • 15.6.3. Nutrimmun GmbH
    • 15.6.4. Kerry Group Plc.
    • 15.6.5. Sabinsa Corporation
    • 15.6.6. Lallemand Health Solutions Inc.
    • 15.6.7. DuPont de Nemours, Inc.
    • 15.6.8. Uplift Food Pty Ltd.
    • 15.6.9. Nature's Bounty Co. Ltd.
    • 15.6.10. BioGaia Group
    • 15.6.11. The Life Extension Foundation
    • 15.6.12. Lifted Naturals

16. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제